Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 3, 2007, Pages 315-320

  Re III, Vincent Lo ^a   Frank, Ian ^a   Gross, Robert ^a   Dockter, Janel ^b   Linnen, Jeffrey M ^b   Giachetti, Cristina ^b   Tebas, Pablo ^a   Stern, John ^a   Synnestvedt, Marie ^a   Localio, A Russell ^a   Kostman, Jay R ^a   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Gen Probe Incorporated   (United States)

Author keywords

HIV; HIV hepatitis B virus coinfection; Occult hepatitis B virus

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EMTRICITABINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; CD4+ T LYMPHOCYTE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; SUPERINFECTION;

ADULT; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHILADELPHIA; PREVALENCE; RISK FACTORS; RNA, VIRAL; STATISTICS AS TOPIC; TRANSAMINASES; VIRAL LOAD;

EID: 33847270112     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802ea499     Document Type: Article

References (37)

1. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003;23:125-136.
2. Santos E, Yoshida CFT, Rolla VC, et al. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis. 2003;22:92-98.
3. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-1745.
4. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9:243-257.
5. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479-486.
6. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology. 2001;34:204-206.
7. Lackner C, Struber G, Liegl B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41:1376-1382.
8. Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, et al. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology. 2005;41:1434-1435.
9. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
10. Al-Mohri H, Cooper C, Murphy T, et al. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med. 2005;6:375-378.
11. McCormick MK, Dockter J. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1, hepatitis C virus RNA, and hepatitis B virus DNA. J Clin Virol. 2006;36:166-176.
12. Linnen J, Phelps B. Implementation of Procleix Ultrio assay on the Procleix TIGRIS system: a fully automated Triplex NAT assay. Presented at: International Plasma Fractionation Association/Paul Ehrlich Institute 12th Nucleic Acid Testing Workshop on Surveillance and Screening of Bloodborne Pathogens; 2005; Bethesda.
13. Katkov WN, Friedman LS, Cody H, et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. Ann Intern Med. 1991;115:882-884.
14. Kratz A, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Normal reference laboratory values. N Engl J Med. 1998;339:1063-1072.
15. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med. 1989;8:771-783.
16. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
17. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 2001;34:194-203.
18. Gandhi RT, Wurcel A, McGovern B, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr. 2003;34:439-441.
19. Hofer M, Joller-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998;17:6-13.
20. Neau D, Winnock M, Jouvencel AC, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis. 2005;40:750-753.
21. Nunez M, Rios P, Perez-Olmeda M, et al. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS. 2002;16:2099-2101.
22. Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol. 2002;36:681-686.
23. Shire NJ, Rouster SD, Rajicic N, et al. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;36:869-875.
24. Wagner AA, Denis F, Weinbreck P, et al. Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS. 2004;18:569-571.
25. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253-1260.
26. Raimondo G, Pollicino T, Squadrito G. What is the clinical impact of occult hepatitis B virus infection? Lancet. 2005;365:638-640.
27. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22-26.
28. De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol. 2000;95:3529-3536.
29. Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? J Hepatol. 2001;34:471-473.
30. Paterlini P, Driss F, Nalpas B, et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993;17:20-29.
31. Kubo S, Tamori A, Ohba K, et al. Previous or occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma without hepatic fibrosis. Dig Dis Sci. 2001;46:2408-2414.
32. Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCVand GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998;29:173-183.
33. Shibata Y, Nakata K, Tsuruta S, et al. Detection of hepatitis B virus X-region DNA in liver tissue from patients with hepatitis C virus-associated cirrhosis who subsequently developed hepatocellular carcinoma. Int J Oncol. 1999;14:1153-1156.
34. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126:102-110.
35. Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol. 2001;63:220-227.
36. Sagnelli E, Coppola N, Scolastico C, et al. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment. J Med Virol. 2001;65:681-687.
37. Zignego AL, Fontana R, Puliti S, et al. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol. 1997;142:535-544.